Policies & RegulationsPharmacyHospitalsPharma & DistributionDrug ApprovalsIP IssuesDomestic NDD
  news bulletin  
Celltrion starts phase III trial for biosimilar Mabthera
by Eui Kyoung Yoon (ekyeun@dreamdrug.com)
Published : Jul 1, 2014 02:56:59
Celltrion got green light to start the phase III clinical trial for its biosimilar of Mabthera (rituximab), the Ministry of Food and Drug Safety said on June 30.

Celltrion plans to conduct its clinical trial in twelve hospitals, including Korea Universtiy Medical Center and Seoul National University Medical Center. It also plans the trial in European countries such as Italy and Spain.

Mabthera sales were 7.6 billion won last year. Samsung Bioepis, Pfizer, Novartis, Merck, Teva, and Boehringer Ingelheim are also working on their biosimilar of Mabthera.
 
Reply 0
Name Password
Text
 
Popular News
 
Champix to be covered, starting Feb 2015
First generic version of Omacor approved
OTC drugs will be available at some resorts
Novartis Korea and KPWA agreed on margin increase
MSD’s new COX-2 inhibitor Arcoxia approved
All materials contained on this site are protected by Korean copyright law and may not be reproduced, distributed, transmitted,
displayed, published or broadcast without the prior consent of dailypharm.com